2025 ADA Standards of Care Highlight Consensus Support for Broader Application of CGM

The recently issued 2025 ADA Standards of Care offered new guidance supporting CGM use in broader patient populations, the application of CGM metrics in achieving glycemic goals, and the integration of CGM with other diabetes technologies at diagnosis.  Specifically, the 2025 Standards of Care recommend considering the use of CGM in adults with T2D NIT to achieve and maintain individualized glycemic goals. Reasserting the clinical value of CGM in type 1 diabetes in pregnancy, the ADA added that CGM may also be beneficial for gestational diabetes and T2D in pregnancy in the 2025 update. ADA also expanded their recommendation for CGM use in individuals with diabetes on any insulin therapy to include youths as well as adults. While previous versions of the Standards of Care stated that CGM metrics should not be used as a substitute for BGM, the 2025 update notes that CGM metrics can be used in conjunction with blood glucose monitoring to achieve glycemic goals. Highlighting the importance of early intervention, the ADA also recommends initiation of CGM, continuous subcutaneous insulin infusion, and automated insulin delivery at diagnosis, depending on a person’s or caregiver’s needs and preferences. These updates are relevant to managed care and payer decision makers in the development of clinically appropriate coverage policies that enhance access to CGM in broader patient populations.

American Diabetes Association Professional Practice Committee. Summary of Revisions: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S6-S13.